SAM
ARTV

Simplify Asset Management’s Artiva Biotherapeutics ARTV Stock Holding History

Simplify Asset Management’s Portfolio ARTV Stock Details ARTV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$983K Buy
101,355
+78,125
+336% +$712K 0.01% 83
2026
Q1 		$150K Buy
+23,230
New +$115K ﹤0.01% 138

Other funds holding ARTV

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return

Simplify Asset Management's ARTV Position: Q2 2026 in Review

Simplify Asset Management increased its Artiva Biotherapeutics (ARTV) stake by 336% in Q2 2026, buying an estimated $712K and bringing the position to 101,355 shares worth $983K. The position accounts for 0.01% of the portfolio, ranked #83.

Simplify Asset Management first reported a position in ARTV in Q1 2026 and has held it in 2 quarters since. 72 funds tracked by Wall St. Rank hold ARTV as of Q2 2026.

  • Simplify Asset Management held 101,355 shares of Artiva Biotherapeutics worth $983K as of Q2 2026.
  • Simplify Asset Management bought 78,125 Artiva Biotherapeutics shares in Q2 2026, an estimated $712K.
  • Artiva Biotherapeutics made up 0.01% of Simplify Asset Management's portfolio in Q2 2026, its #83 holding.
  • Simplify Asset Management first reported a position in Artiva Biotherapeutics in Q1 2026 and has held it in 2 quarters since.
  • 72 funds tracked by Wall St. Rank held Artiva Biotherapeutics as of Q2 2026.

Based on Simplify Asset Management's 13F filing for Q2 2026, filed 16 Jul 2026.